Hisamitsu Pharmaceutical Company, Inc.

Yuka Takagi

Yasunari Michinaka

Naoyuki Uchida

Masaki Yukuhiro

Yoko Fujiwara

Hiroaki Kobayashi

Yasunori Takada

Takashi Yasukochi

Satoshi Amano

Toshiro Yamaguchi

Takao Kurokawa

Takuya Umemoto

Hiroyuki Araki

The present invention provides a patch comprising an adhesive layer on a backing, the adhesive layer comprising: asenapine or a pharmaceutically acceptable salt thereof; an adhesive base; and at least one selected from the group consisting of thiosulfates, sulfites, and pyrosulfites.

Method for suppressing production of asenapine-N-oxide

An object of the present invention is to provide an asenapine-containing patch having excellent adhesiveness and handleability, which can persistently provide sufficient medicinal effects by suppressing cold flow during storage or application while enhancing skin permeability using a silicone-based pressure-sensitive adhesive base, and thereby maintaining the stability of the drug in the patch during storage, and maintaining an appropriate administration form for a long period of time. The present invention relates to a patch having a support and a pressure-sensitive adhesive layer, wherein the pressure-sensitive adhesive layer comprises asenapine and a silicone-based pressure-sensitive adhesive base, and the loss tangent (tan δ) of the pressure-sensitive adhesive layer is 0.75 to 1.5 at 1.0 Hz.

Asenapine-containing adhesive patch

The present invention provides a rotigotine-containing patch comprising: a backing layer; and an adhesive agent layer, wherein the adhesive agent layer contains rotigotine and/or a pharmaceutically acceptable salt thereof, the adhesive agent layer further contains a styrene-based thermoplastic elastomer, a petroleum-based resin and/or a terpene-based resin, an aliphatic alcohol, and a cross-linked polyvinylpyrrolidone, and in the adhesive agent layer, a mass ratio of a content of the rotigotine and/or the pharmaceutically acceptable salt thereof in terms of rotigotine free form and a content of the cross-linked polyvinylpyrrolidone (content of the rotigotine and/or the pharmaceutically acceptable salt thereof in terms of rotigotine free form:content of the cross-linked polyvinylpyrrolidone) is 10:3 to 1:3.

Rotigotine-containing patch

An object of the present invention is to provide an asenapine-containing patch having excellent sustained-release properties while enhancing skin permeability by using a silicone-based pressure-sensitive adhesive base. The present invention relates to a patch having a support and a pressure-sensitive adhesive layer, wherein the pressure-sensitive adhesive layer comprises asenapine and/or a pharmaceutically acceptable salt thereof, a silicone-based pressure-sensitive adhesive base and a release control agent, and the ratio of the maximum skin permeation rate of asenapine to the minimum skin permeation rate from the time when the maximum skin permeation rate is reached to 24 hours is less than 1.62.

A patch includes an adhesive layer and a release liner laminated on at least one surface of a backing. The adhesive layer comprises, as an adhesive base agent, at least one selected from the group consisting of acrylate-based adhesives and rubber-based adhesives, and the adhesive layer comprises 0.3 to 5% by mass of a nonfunctional silicone oil having a kinematic viscosity of 10 to 350 cSt at 25&#xb0; C.

Patch comprising an adhesive layer having a nonfunctional silicone oil

A ropinirole-containing patch comprises an adhesive agent layer and a support layer, the adhesive agent layer containing ropinirole and/or a pharmaceutically acceptable salt thereof, wherein a content of the ropinirole and/or the pharmaceutically acceptable salt thereof in terms of free ropinirole in the adhesive agent layer satisfies the following two conditions:

Ropinirole-containing patch and package thereof

A patch comprising a support layer and an adhesive agent layer, wherein the adhesive agent layer comprises at least one drug selected from the group consisting of emedastine and pharmaceutically acceptable salts thereof, at least one adhesive agent selected from the group consisting of rubber-based adhesive agents and silicone-based adhesive agents, and an alkali metal fumarate as a cohesive force-improving agent for the adhesive agent layer.

Patch

The present invention relates to a transdermal preparation having a backing and an adhesive layer laminated on the backing, wherein the adhesive layer contains 4-ethylene-2(3H)-indolone and a physiologically active compound, and wherein the 4-ethylene-2(3H)-indolone is present in an amount from 0.001 to 4 mass % of the total mass of components of the adhesive layer.

Transdermal preparation comprising a ropinirole derivative

A ropinirole-containing patch comprises an adhesive agent layer and a support layer, the adhesive agent layer containing ropinirole and/or a pharmaceutically acceptable salt thereof, wherein

Growing community of inventors

Tsukuba, Japan

Yuka Takagi